Table 3.

Bone marrow cellularity and percentage of normal B cells and CLL cells on ibrutinib

	Cellularity, %	CLL cells of total lymphocytes, %	Normal B cells of total lymphocytes, %
Pretreatment
Patients	n = 69	n = 13	n = 13
Median (min-max)	75 (30-100)	95 (19-99)	0.00* (0-1.49)
12 mo
Patients	n = 55	n = 30	n = 29
Median (min-max)	45 (5-90)	68 (17-97)	0.33* (0-8.19)
24 mo
Patients	n = 38	n = 58	n = 35
Median (min-max)	50 (15-80)	58 (2-97)	0.54* (0-17.93)

^*P = .01 and .002 in an unpaired Wilcoxon analysis comparing normal B cells at pretreatment to 12 and 24 mo, respectively.